Ridgeback Biotherapeutics, LP   Report issue

For profit Phase 2
Founded: Miami FL United States (2016)

Organization Overview

First Clinical Trial
2020
NCT04392219
First Marketed Drug
2020
ANSUVIMAB (Ebanga)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

RIDGEBACK BIOTHERAPEUTICS | Ridgeback Biotherapeutics, LP

Active Ingredients

Marketed Drugs (1)

ANSUVIMAB (Ebanga) (2020)

Drugs in Phase 2 Trials (1)

Molnupiravir (3 trials)

Drugs in Other Trials (1)

ANSUVIMAB (Ebanga) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Coronavirus Infections (Phase 1)

Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2